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Abstract
Aims/hypothesis Targeting the secretion of gut peptides
such as glucagon-like peptide 1 (GLP-1) and peptide YY
(PYY) is a strategy under development for the treatment of
diabetes and obesity, aiming to mimic the beneficial alter-
ations in intestinal physiology that follow gastric bypass
surgery. In vitro systems are now well established for study-
ing the mouse enteroendocrine system, but whether these
accurately model the human gut remains unclear. The aim of
this study was to establish and characterise human primary
intestinal cultures as a model for assessing GLP-1 and PYY
secretion in vitro.
Methods Fresh surgical biopsies of human colon were
digested with collagenase to generate primary cultures from
which GLP-1 and PYY secretion were assayed in response
to test stimuli. GLP-1 and PYY co-localisation were
assessed by flow cytometry and immunofluorescence
microscopy.
Results GLP-1 and PYY were found localised in the same
cells and the same secretory vesicles in human colonic tissue
samples. GLP-1 release was increased to 2.6-fold the control
value by forskolin+isobutylmethylxanthine (10 μmol/l
each), 2.8-fold by phorbol myristate acetate (1 μmol/l) and
1.4-fold by linoleic acid (100 μmol/l). PYY release was
increased to 2.0-, 1.8- and 1.3-fold by the same stimuli,
respectively. Agonists of G-protein-coupled receptor
(GPR)40/120 and G-protein-coupled bile acid receptor 1
(GPBAR1) each increased GLP-1 release to 1.5-fold, but a
GPR119 agonist did not significantly stimulate secretion.
Conclusions/interpretation Primary human colonic cultures
provide an in vitro model for interrogating the human
enteroendocrine system, and co-secrete GLP-1 and PYY.
We found no evidence of PYY-specific cells not producing
GLP-1. GLP-1 secretion was enhanced by small molecule
agonists of GPR40/120 and GPBAR1.
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Abbreviations
FFAR1 Free fatty acid receptor 1
FSK Forskolin
GLP-1 Glucagon-like peptide 1
GPBAR1 G-protein-coupled bile acid receptor 1
GPR G-protein-coupled receptor
IBMX Isobutylmethylxanthine
PMA Phorbol myristate acetate
PYY Peptide YY
Introduction
The intestinal epithelium produces a variety of hormones
that enhance insulin release and satiety. Among these,
glucagon-like peptide 1 (GLP-1) has received attention for
its ability to increase glucose-dependent insulin release and
reduce food intake, and these properties have been
harnessed in the form of GLP-1 mimetics and dipeptidyl
peptidase 4 inhibitors for the treatment of type 2 diabetes
[1]. The mechanisms underlying its secretion have recently
been characterised using a range of murine in vitro systems
[2], but equivalent data are currently lacking for humans.
GLP-1 is secreted by entero-endocrine L cells found
scattered in the intestinal epithelium. L cells increase in
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density along the proximal–distal gut axis. In addition, they
exhibit longitudinal variation in the spectrum of hormones
found co-localised with GLP-1. We recently reported that, in
the mouse gut, a high proportion of L cells in the upper
small intestine produce cholecystokinin, whereas the per-
centage of L cells containing the anorectic hormone peptide
YY (PYY) increases progressively towards the colon [3].
Despite the findings that PYY is predominantly co-located
with GLP-1 in the mouse gut and that plasma levels of
both PYY and GLP-1 rise after a meal, there seem to be
some conditions that favour release of one hormone over
the other [4]. Whether this is due to the activation of
different L cell pools, the differential release of PYY and
GLP-1 from the same secretory L cells or the existence of
PYY-positive but GLP-1-negative cells, remains to be
established.
In view of the production by L cells of a number of
peptides that reduce appetite and lower plasma glucose,
the idea of targeting this cell population for the treatment
of diabetes and obesity is an area of therapeutic develop-
ment. There are ongoing clinical and preclinical trials of a
number of agents that activate L cell-specific G-protein-
coupled receptors, such as the long-chain NEFA receptors
(free fatty acid receptor 1 [FFAR1], G-protein-coupled recep-
tor [GPR]120, GPR119) and the bile acid receptor G-protein-
coupled bile acid receptor 1 (GPBAR1, also referred to as
TGR5). Whether this strategy will work in humans remains to
be definitively established, but the idea is supported by an
increasing body of evidence that the gut endocrine system
underlies many of the beneficial effects of gastric bypass on
glycaemia and appetite [5]. In vitro models for the human
L cell are critically needed, and the aims of this study were to
devise methods to maintain human L cells in primary culture
and to examine the effects of different G-protein-coupled
receptor agonists on GLP-1 and PYY release.
Methods
Primary culture The study was approved by the local re-
search ethics committee. Fresh anonymised surgical speci-
mens of human colon were obtained from Tissue Bank at
Addenbrooke’s Hospital, Cambridge, stored at 4°C and
processed within hours of surgery. Tissue samples (∼0.5 g
in weight) were dissected free of muscle and connective
tissue, rinsed, minced and digested four times (20 min each)
with collagenase XI (0.5 mg/ml) in DMEM (4.5 g/l glucose)
at 37°C. Supernatant fractions from each digest were
centrifuged twice at 100g for 3 min to pellet crypts, which
were resuspended in 7 ml culture medium (DMEM
supplemented with 10% (vol./vol.) fetal bovine serum,
2 mmol/l L-glutamine, 100 units/ml penicillin and 0.1 mg/ml
streptomycin). Aliquots (250 μl) were plated into 24-well
plates or glass coverslips coated thinly with Matrigel (BD
Bioscience, Oxford, UK). During overnight incubation at
37°C in 5% CO2, cells spread out to form a partial mono-
layer, similar in appearance to cultures from mouse colon
that typically remain viable for up to 10 days [6].
Immunostaining After 16 h in culture, cells were fixed in
4% (wt./vol.) paraformaldehyde, washed three times with
PBS, and blocked in a solution of 5% (vol./vol.) goat serum,
0.1% (vol./vol.) Triton X-100 in PBS for 30 min. Samples
were incubated with guinea pig anti-PYY antibody (1:100;
catalogue number 16066; Progen, London, UK;) and rabbit
anti-proglucagon antibody (1:200; catalogue number sc-
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Fig. 1 Co-localisation of GLP-1 and PYY in human colonic L cells.
(a,b) Paraformaldehyde-fixed colonic cell suspensions analysed by
flow cytometry. Points in (b) depict the staining of individual cells
for GLP (x-axis) vs PYY (y-axis). Both primary antibodies were
omitted in the control (a). The position of double-positive cells is
delineated by the oval. (c) The 16-h-old cultures were co-stained with
primary antibodies to PYY (red) and GLP (green). Co-localisation of
PYY and GLP immunofluorescence in a single L cell is shown (over-
lay, yellow). Nuclei were visualised with DAPI (blue). Images were
captured using a ×63 objective lens. The scale bar represents 10 μm
1414 Diabetologia (2013) 56:1413–1416
washed three times with 5% goat serum in PBS, and then
incubated with Alexa-Fluor 633 anti-guinea pig and Alexa-
Fluor 488 anti-rabbit antibodies (1:300 each; Invitrogen,
Carlsbad, CA, USA) for a further hour. Control staining
was performed by omitting proglucagon and/or PYY prima-
ry antibodies.
Flow cytometry Colonic biopsies were stripped of connec-
tive tissue, minced and digested twice with 1.25 mg/ml
collagenase (type XI) in Hanks’ buffered salt solution for
30 min at 37°C. After gentle trituration using a 10 ml pipette
and filtering, the resultant single-cell suspension was fixed
with 4% (wt./vol.) paraformaldehyde in PBS for 30 min at
room temperature. Cell suspensions were incubated over-
night in PBS–10% (vol./vol.) goat serum at 4°C and
permeabilised with 10% goat serum, 0.3% Triton X-100 in
PBS. Pellets were incubated in PBS–10% goat serum
with/without proglucagon (1:200) and PYY (1:100) primary
antibodies (as above) for 1 h. Cells were rinsed three times
in PBS–10% goat serum and then incubated with secondary
antibodies (as above; 1:1,000) for 30 min. After three further
washes, cells were analysed using a BD LSRFortessa
analyser (BD Biosciences, San Jose, CA, USA) equipped
with 488 and 640 nm lasers. Data were analysed using
FlowJo 7.6 software (Tree Star, Ashland, OR, USA).
GLP-1 and PYY secretion Cultures were incubated with test
reagents in saline buffer containing (in mmol/l) 4.5 KCl, 138
NaCl, 4.2 NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2, 1.2 MgCl2,
10 HEPES and 10 glucose (pH7.4, NaOH) plus 0.1% fatty
acid-free BSA, for 2 h at 37°C. At the end of the incubation,
cells were lysed with buffer containing: 50 mmol/l Tris–
HCl, 150 mmol/l NaCl, 1% (vol./vol.) IGEPAL CA-630,
0.5% (wt./vol.) deoxycholic acid and one tablet of protease
inhibitor cocktail (Roche Diagnostics, Burgess Hill, UK),
and mechanically disrupted to extract intracellular peptides.
Supernatants and lysates were assayed for active GLP-1
and/or total PYY by ELISA (Millipore, USA). Hormone
secretion was expressed as a fraction of the total hormone
content per well, normalised to basal secretion measured in
parallel control wells. Forskolin (FSK, 10 μmol),
isobutylmethylxanthine (IBMX, 10 μmol/l), phorbol
myristate acetate (PMA, 1 μmol/l), GW9508 (100 μmol/l),
AR231453 (10 nmol/l) and GPBAR1-A (3 μmol/l; Roche,
Basel), were added from 1,000x stocks in DMSO. GW9508
and AR231453 were synthesised by AstraZeneca
(Macclesfield, UK) and supplied as a kind gift. Linoleic acid
was applied at 100 μmol/l from a 5 mmol/l stock prepared in
saline buffer+5% (wt/vol.) BSA. All chemicals were obtained
from Sigma (Poole, UK), unless otherwise stated.
Statistical analysis One-sample Student’s t tests were
performed using Microsoft Excel to test the null hypothesis
that the data were from a population of mean=1. A p value
of less than 0.05 was considered significant.
Results
Co-localisation of GLP-1 and PYY in human colonic L
cells Dissociated human colonic biopsies were immuno-
stained in suspension for GLP-1 and PYY and analysed by
flow cytometry. A distinct population of double immuno-
positive cells, comprising 0.86±0.26% (n=4) of the total
cell count, was evident in samples incubated with primary
antibodies against GLP-1 and PYY (Fig. 1a,b). No signifi-
cant populations were detected that were positive for only
one of the two hormones.
Protocols were developed for the primary culture of


























































































Fig. 2 GLP-1 and PYY secretion from primary human colonic cul-
tures. The 1-day-old colonic cultures were incubated for 2 h in FSK+
IBMX (10 μmol/l each), PMA (1 μmol/l) or linoleic acid (100 μmol/l).
GLP-1 (a) and PYY (b) were assayed in the supernatant fraction and
cell lysate to calculate the percentage of cell content released, and then
normalised to the basal release measured in parallel control wells
containing buffer with no additions. Error bars represent 1 SEM of
the number of wells indicated. Mean basal GLP-1 and PYY release
was 1.1±0.3% and 2.6±0.4%, respectively, of the total cell content at
2 h. (c) Cultures were incubated with GW9508 (GW, 100 μmol/l),
GPBAR1-A (GPB, 3 μmol/l) or AR231453 (AR, 10 nmol/l), and
assayed for GLP-1 as in (a). *p<0.05, ***p<0.001
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fixed with paraformaldehyde, L cells were readily identifi-
able by immunofluorescence. Consistent with the FACS
results, GLP-1 and PYY were found localised in the same
cells, and were detectable by confocal microscopy in the
same secretory vesicles (Fig. 1c).
Co-secretion of GLP-1 and PYY from human colonic
cultures To monitor the secretion of GLP-1 and PYY from
primary human colonic cultures, cells were incubated for 2 h
with test stimuli. GLP-1 release was enhanced to 2.6-fold the
control value by FSK+IBMX, 2.8-fold by PMA and 1.4-fold
by linoleic acid (Fig. 2a). PYY release mirrored the profile of
GLP-1 secretion (Fig. 2b), consistent with the observed
localisation of both peptides to the same cell and vesicle
populations. GLP-1 responses to agonists of GPR40/120,
GPR119 and GPBAR1 were also examined, using the com-
pounds GW9508 [7], AR231453 [8] and GPBAR1-A [9],
respectively. Stimulation of GPR40/120 and GPBAR1, but
not GPR119, enhanced GLP-1 secretion (Fig. 2c).
Discussion
Human L cells survived in mixed primary colonic epithelial
cultures and were activated by physiological stimuli. GLP-1
and PYY were co-localised in the same vesicle pools, as
described previously [4], with no detectable cell population
producing only one of the two peptides. Consistent with the
strong co-localisation of the two peptides by FACS analysis
and in primary cultures, both were released in parallel in
secretion assays.
Surprisingly, the primary human cultures released GLP-1
in response to agonists of FFAR1/GPR120 and GPBAR1,
but were not significantly activated by the GPR119 agonist
AR231453. In comparative studies using mouse colonic
cultures prepared with similar protocols, the same
compounds/concentrations triggered GLP-1 release to 3.4-,
4.2- and 2.3-fold of control values, respectively (data not
shown), and FSK+IBMX increased secretion ∼10-fold [6].
Thus, across all stimuli, human cultures exhibited ∼4-fold
lower responsiveness than murine cultures, despite similar
basal rates of secretion (1.1±0.3% and 1.3±0.3% of the total
GLP-1 content per 2 h, respectively). Whether this reflects a
genuine difference in responsiveness between human vs
mouse L cells, or is a consequence of the dissociation and
culture conditions employed, cannot be established from our
data. In the face of the lower general responsiveness of
human than murine cultures, responses to weaker stimuli
were less readily detectable, perhaps explaining the lack of a
significant stimulation by AR231453 in this study. The
possibility that GPR119 agonists may be relatively poor
stimuli in the human colon should, however, be considered,
in the light of some recent disappointing metabolic re-
sponses to GPR119 agonists in clinical trials [10].
Translating findings from mouse to human is a crucial
step in drug development. The primary human intestinal
cultures described here provide an in vitro system that
should help to bridge this technological gap.
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